The current study provides a strong rationale to target mesothelin in advanced lung adenocarcinoma and suggest that clinical trials of mesothelin-directed therapies in lung cancer should focus on patients with KRAS mutations, the most commonly mutated oncogene in NSCLC and one which has proven intractable even in the era of targeted therapy. The gene discussed is MSLN; the disease is non-small cell lung carcinoma.